Font size

Visual China Map

Another listed drug company has tax problems.

on the evening of June 21, kexing biopharmaceutical co., ltd. (kexing pharmaceutical, 688136) announced that the company had recently paid back taxes and late fees totaling 21.3111 million yuan.

according to the announcement, the first inspection bureau of Jinan municipal taxation bureau of the state administration of taxation has inspected the tax-related situation of the company from January 1, 2021 to December 31, 2022. the company should repay the enterprise income tax of 15.4877 million yuan in 2021 and pay a late fee of 5.8234 million yuan (as of the actual payment date), totaling 21.3111 million yuan. The Company has paid the above taxes and late fees as required, and the competent tax authorities have not imposed penalties on the matter.

2023 financial report shows that Kexing Pharmaceutical's operating income in 2023 was 1.259 billion yuan, down 4.32 percent year-on-year; net profit attributable to the parent expanded to 0.19 billion yuan. According to the first quarter report of 2024, the company's operating income was 0.361 billion yuan, up 11.79 percent from the same period last year, while the net profit of the parent company turned from loss to profit, reaching 12.4034 million yuan.

regarding the impact of the penalty on the company's performance, kexing pharmaceutical said that the company's supplementary payment of the above taxes and late fees will be included in the current profit and loss in 2024, which is expected to affect the company's net profit of about 21.3111 million yuan in 2024, and the audited financial statements in 2024 shall prevail.

Kexing Pharmaceutical also emphasized that the company's management attaches great importance to the above matters and will continue to strengthen the company's tax management, organize relevant departments and personnel to train and learn financial and taxation knowledge, strengthen the sense of responsibility, and effectively safeguard the company and shareholders. Interests.

according to the official website, the history of kexing pharmaceutical can be traced back to Shenzhen kexing, which was established in 1989. in 1997, Shandong kexing (now kexing pharmaceutical) was established. in 2019, the company was restructured into "kexing biopharmaceutical co., ltd." and listed on the board in 2020. At present, the main business of Kexing Pharmaceutical is the research and development, production and sales of recombinant protein drugs and microecological preparations, covering antiviral, tumor and immune, blood, digestive, degenerative diseases and other therapeutic fields.

It is worth noting that Kexing Pharmaceuticals is not the same company as Kexing, which researches the new crown vaccine. As early as June 2021, Kexing Pharmaceuticals had announced that the new crown vaccine (Vero cells) was conditionally approved for listing for Beijing Kexing Zhongwei Biotechnology Co. The company is not the same company as Beijing Kexing Zhongwei Biotechnology Co., Ltd., and has no equity relationship or related relationship with Beijing Kexing Zhongwei Biotechnology Co., Ltd.

This is not the first listed drug company to have tax problems recently. On April 25, Peking University Pharmaceutical announced that after the company's self-examination, the company needs to pay a total of 13.8202 million yuan in value-added tax, enterprise income tax, urban maintenance and construction tax, education surcharge and local education surcharge for the period from 2019 to May 31, 2023, with a total late fee of 5.6271 million yuan (as of the actual payment date) and a total of 19.4473 million yuan. The Company has paid the above taxes and late fees as required.

Peking University Pharmaceutical said that the company's supplementary payment of the above taxes and late fees will be included in the current profit and loss of 18.7252 million yuan in 2023 and 722100 yuan in 2024. The management of the company attaches great importance to the above matters, and will continue to strengthen the company's tax management, organize relevant departments and personnel to train and learn financial and tax knowledge, strengthen the sense of responsibility, and effectively safeguard the interests of the company and shareholders.

On June 18, responsible persons of relevant departments of the State Administration of Taxation answered reporters' questions. With regard to the situation that the tax authorities in some areas have "backchecked for 30 years" and asked enterprises to make up taxes, the person in charge of the relevant departments said that the State Administration of Taxation has paid attention to the relevant reflection and fully understood the concerns of the broad masses of business entities and the public. The tax department has not organized a national, industrial, and centralized tax inspection, let alone a 20-year or 30-year arrangement.

the person in charge of the relevant departments said that some of the recent reports on tax inspection and compensation include the collection of taxes owed by enterprises in previous years according to procedures, and some of them are prompted and informed according to procedures of the applicable risks of tax policies existing in enterprises, all of which are routine and normal performance of duties in accordance with laws and regulations by tax departments.

Editor: Sun Fu

photo editor: Shi jiahui surging news: 021-962866 surging news, no reprinting without authorization